Dual Approach of Next-Gen Vectorized Gene Therapy and Vectorized Antibodies
Revolutionizing Treatment for Neurodegenerative Diseases and Beyond
The promise of vectorized gene therapy has ignited a beacon of hope for individuals battling debilitating central nervous system (CNS) proteinopathies and rare neurological diseases. Our groundbreaking pipeline, spearheaded by state-of-the-art vectorized gene therapy, is poised to halt disease progression and restore function in patients grappling with some of the most challenging diseases and conditions to treat.
At the forefront of our efforts are two devastating CNS diseases – 4H Leukodystrophy and Early Onset Parkinson’s Disease (EOPD). For 4H Leukodystrophy, a rare pediatric disease, we are developing LNP-mRNA therapies which deliver mRNAs that code for therapeutic functional proteins which instruct cells to produce beneficial proteins. Upregulating expression of the PINK1 and/or Parkin genes and clearing toxic protein are the goals of our EOPD therapy which leverages our proprietary vectorized nanoantibody platform.
For aggressive cancers, we are deploying a "smart" gene therapy system that works in tandem with antibody-drug conjugates (ADCs). This dual approach with trispecific nanoantibody drug conjugates uses vectors carrying tumor suppressor genes (TSGs) - the good guys that fight cancer growth to tackle the hardest cancer to treat such as Triple Negative Breast Cancer (TNBC).
Focusing on Next- Gen Vectors to Deliver Gene Therapy with Precision
Our current pipeline of therapeutics for neurodegenerative diseases uses novel non-viral and AAV vectors that can more efficiently and effectively deliver the therapy to the targeted areas. Leveraging our decades of experience in nano-science technology with cutting-edge genomic therapeutic targets, Canary is poised to develop a comprehensive and lasting solution for the most difficult diseases to treat.
Developing World’s First Treatment for 4H Leukodystrophy
At the forefront of our pipeline is a gene therapy for a devastating rare pediatric neurodegenerative disease. Our proprietary LNP formulations enhance stability and intracellular mRNA release, maximizing therapeutic efficacy. We aim to restore function and replace missing proteins.
Pioneering Treatments for Rheumatoid Arthritis
Within our pipeline, we are spearheading groundbreaking research aimed at curing Rheumatoid Arthritis (RA), an autoimmune disorder that causes chronic inflammation and joint damage. Our approach utilizes cutting-edge gene therapy to modulate the immune system and halt the destructive processes underlying the disorder.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
